Regenerative Medical Technologies Group, Inc. (RMTG) is a regenerative medicine company in the healthcare and biotechnology space, operating globally through its Global Stem Cells Group subsidiary. The RMTG news feed on Stock Titan highlights how the company combines stem cell and cellular therapies, biologic manufacturing, and physician education to build its presence in more than 30 countries.
News coverage for RMTG often focuses on international expansion and affiliate agreements, such as representation and partnership deals in Puerto Rico, northern Argentina and Paraguay, Brazil, and the Dominican Republic. These stories describe how local medical leaders are appointed to develop regional centers, training programs, and product distribution networks under the Global Stem Cells Group and ISSCA brands.
Another major theme in RMTG news is education and training events. Press releases detail ISSCA summits and in-country programs that bring together physicians and scientists for lectures, hands-on workshops, and certification in regenerative medicine protocols. These events generate revenue through registration fees, certification programs, exhibitor opportunities, and product sales, and they showcase the company’s CELLGENIC product line and manufacturing capabilities.
RMTG news also covers manufacturing developments and strategic partnerships, including the soft opening of an advanced cell therapy manufacturing facility in Cancún, Mexico, and a partnership with Bare Knuckle Fighting Championship to provide stem cell and regenerative treatments for fighters’ injuries. Financial updates, such as year-over-year sales growth and operating income, appear in earnings-related press releases.
Investors and healthcare professionals can use the RMTG news page to follow updates on geographic expansion, new affiliates, education initiatives, manufacturing milestones, and business performance as disclosed by the company.
Regenerative Medical Technology Group (RMTG) has expanded its ISSCA division’s Online Academy with ten new curriculum tracks covering regenerative-medicine topics.
The curriculum covers biologics, exosomes, mesenchymal stromal/stem cells, Natural Killer cells, dendritic cells, immunotherapy, CAR-T cell science, peptide medicine and longevity medicine, alongside other emerging technologies. The company says the expansion is intended to give physicians outside its in-person conference markets ongoing access to updated education.
The modules provide physician education, not authorization to administer therapies; authorization remains subject to each physician’s licensure and applicable local regulation.
Regenerative Medical Technology Group (RMTG) launched a Longevity and Adjunctive Therapies Certification through ISSCA, its physician-education division within Global Stem Cells Group.
The curriculum covers multiple complementary technologies rather than certifying a single treatment. RMTG intends it to complement capabilities its Cellular Hope Institute clinic in Cancún is separately evaluating or developing; not every covered technology is currently offered, authorized or available there. ISSCA certifications are company-issued educational credentials, not governmental or board-specialty accreditation. The program makes no claim of safety, efficacy or regulatory clearance for the technologies.
Regenerative Medical Technology Group (RMTG) launched Peptide Certification 2.0 through its ISSCA division, updating an existing physician-education program.
The international program adds updated educational modules and two physician reference guides covering preparation, program design and clinical decision-making. RMTG intends the program to connect physician training more closely with Cellgenic's peptide product portfolio where permitted. ISSCA certifications are company-issued educational credentials, not governmental or board-specialty accreditation. The program does not replace medical licensure, product labeling or regulatory authorization.
Regenerative Medical Technology Group (RMTG) will host the 2026 ISSCA Global Summit, ISSCA 125, from September 25-27 at the JW Marriott Cancún Resort & Spa in Mexico.
The event, organized through RMTG’s ISSCA division within Global Stem Cells Group, is expected to attract hundreds of physicians and healthcare professionals from more than 50 countries and be ISSCA’s largest 2026 program. The three-day summit will feature five specialty certification tracks in peptide medicine, longevity, regenerative aesthetics, musculoskeletal medicine, and MSCs and exosomes, plus an international scientific conference with faculty from regenerative medicine and biotechnology.
RMTG views the summit as a way to expand physician education and international commercial engagement. ISSCA certifications are described as educational credentials, not U.S. specialty-board certifications or regulatory product approvals.
Regenerative Medical Technology Group (RMTG) announced that its ISSCA division has launched an Integrative Fellowship in Point-of-Care Regenerative Medicine, positioned as ISSCA's most comprehensive and longer-duration physician credential within its global education platform.
The fellowship curriculum integrates regenerative medicine, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence. Management intends to use the program as an educational onboarding channel into ISSCA AI™, a physician-controlled clinical-intelligence platform designed to support structured data review and workflow while leaving clinical decisions to physicians. RMTG reports that, across Global Stem Cells Group businesses, more than 12,000 physicians have been trained and its network spans over 30 countries, though these figures do not represent current ISSCA AI™ subscribers or fellowship enrollment.
Regenerative Medical Technology Group (RMTG) detailed an expanded ISSCA AI™ Clinical Intelligence Platform for regenerative and longevity clinics, outlining clinical functions, protocol integration, and a multi-line commercial model as of September 14, 2026.
The physician-facing system is designed to ingest lab-report PDFs, extract biomarkers, calculate biological-age and system-level risk scores, and draft intervention plans for physician review, with a patient app mirroring selected data and integrating wearable and lifestyle inputs. The platform's Florence engine is built on a reasoning corpus of 1.6 million longitudinal electronic health records over 30 years plus more than 10,000 clinical studies, and is described as HIPAA-aligned with physician-in-the-loop controls. ISSCA is ingesting its own training materials and dosing protocols so the engine operates on ISSCA methodology, supported by SaaS subscriptions, patient memberships, conference-driven sales, and an ISSCA AI™ certification program.
Regenerative Medical Technology Group (RMTG) announced that its Cellgenic division has begun local commercial setup activities in Colombia, including establishing local representation and engaging physicians and medical providers in permitted channels.
Colombia is the third Latin American market for recent Cellgenic commercial arrangements, following Peru and Brazil. All Colombian activities remain subject to local regulatory, import, professional-licensing, and contractual requirements and do not imply completed product registration, U.S. commercialization, or FDA approval. Management expects a ramp period for licensing, staffing, import logistics, and physician onboarding and is not providing revenue, physician-count, or product-demand guidance. The company continues to face going-concern uncertainty, limited liquidity, substantial indebtedness, and potential dilution as disclosed in its SEC filings.
Regenerative Medical Technology Group (RMTG) announced that its Cellgenic division has expanded its local commercial presence in Brazil through enhanced representation and physician-facing support. The buildout aims to strengthen physician relationships and support product distribution in permitted channels, while remaining fully subject to Brazilian law and ANVISA and other regulatory requirements.
Management treats Brazil as Cellgenic’s largest active Latin American expansion market and is shifting from a representation-only model toward a more permanent commercial footprint. The company links Cellgenic’s expanded Brazil operations with ISSCA’s ongoing physician-education conferences in São Paulo as a two-channel entry strategy focused on education and commercial infrastructure, with progress dependent on regulation, physician adoption, and available funding.
Regenerative Medical Technology Group (OTCID:RMTG) announced that its Cellgenic division has commenced commercial activity in Peru through local commercial arrangements, including exclusive representation in permitted channels, subject to Peruvian regulatory requirements. Cellgenic products are offered only to licensed physicians and clinics in markets where such distribution is allowed by local law.
The Peru launch extends Cellgenic's Latin American commercial network, which is being built via market entries and partnerships. Peru is one of three coordinated initiatives, alongside Brazil and Colombia, in Cellgenic's current regional growth phase. The company has not determined that the Peru arrangements will be material and states there is no assurance they will generate meaningful or recurring revenue.
Regenerative Medical Technology Group (OTCID:RMTG) announced that its Cellgenic division has introduced a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets, including Latin America, the Middle East, Europe, and Southeast Asia, subject to local regulatory requirements. MUSE cells are pluripotent-like stem cells identified in adult tissue and studied for stress tolerance and multilineage differentiation. The launch follows Cellgenic’s August 24, 2026 introduction of a Natural Killer (NK) cell product line, reflecting a strategy of sequential, technology-specific product rollouts to expand Cellgenic’s advanced cellular-technology portfolio and support a repeatable product-development and market-entry model. The company states it is not making therapeutic claims in this announcement.